News ReleaseView printer-friendly version
Quidel Board Elects Mark A. Pulido Chairman
SAN DIEGO, Calif.--(BUSINESS WIRE)--June 2, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of point-of-care rapid diagnostic tests, today announced that Mark A. Pulido, 51, has been elected non-executive chairman of the company's board of directors. Mr. Pulido, a Quidel director for the past two years, succeeds Andre de Bruin, who has retired from the board.
"Quidel faces a promising future in developing next-generation rapid diagnostic testing products for use at the point of patient care. With our leading brands and new product technology, we are committed to delivering consistent, profitable growth," Mr. Pulido said.
S. Wayne Kay, president and chief executive officer of Quidel, commented, "Quidel is fortunate to have Mark Pulido agree to serve as chairman. With a 25-year career in the healthcare industry, he has brought exceptional depth and knowledge to Quidel as a director."
Mr. Pulido has served as chairman of the board of BenefitPoint, Inc., where he was also the company's president and chief executive officer. While at BenefitPoint, he was credited with creating the industry standard in the $600 billion employee benefits industry. Prior to BenefitPoint, Mr. Pulido was president and chief executive officer of McKesson Corporation (NYSE:MCK), a Fortune 16 healthcare services and information technology company. He also was president and chief executive officer of Sandoz Pharmaceuticals (now Novartis (NYSE:NVS)) and RedLine Healthcare Corporation.
Mr. Pulido is a director of Sunrise Medical, and has served on the boards of McKesson, Charles Schwab and Imation. He holds a Bachelor of Science degree in pharmacy from the University of Arizona, College of Pharmacy and a Master of Science degree in pharmacy administration from the University of Minnesota, College of Pharmacy. In addition, Mr. Pulido is a National Trustee of the Boys and Girls Clubs of America and serves as a Trustee of the Burnham Institute and the Rancho Santa Fe School Endowment.
Quidel Corporation, a worldwide company dedicated to helping women and their families live healthy lives, discovers, develops, manufactures and markets point-of-care (POC) rapid diagnostic tests for detecting medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions in areas including reproduction, upper respiratory infections and other clinical conditions. Quidel provides a broad line of POC diagnostics for pregnancy and infectious diseases, including influenza A and B, Strep throat, pregnancy, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and to consumers through several distribution partners. For more information, please visit www.quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks and uncertainties. Many possible events or factors could affect Quidel's future financial results and performance, such that its actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, intellectual property, product liability, environmental or other litigation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (FDA), and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (SEC) from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
Lippert/Heilshorn & Associates
Bruce Voss/Ina McGuinness, 310-691-7100
SOURCE: Quidel Corporation